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Executive Summary
Methamphetamine is a drug of abuse, which is often produced in clandestine laboratories.
Recent efforts to curb methamphetamine abuse are aimed at controlling access to precursors,
including pseudoephedrine (PSE), used in illicit methamphetamine production. Currently, access
to PSE is controlled in Kentucky by placement behind pharmacy counters, retail quantity
limitations and electronic tracking. Recent legislation proposed in Kentucky to change PSE from
non-prescription to a legend medication was unsuccessful and highly controversial. The
objective of this project is to collect and analyze pharmacists’ opinions on the effectiveness of
current precursor controls, proposed legislation to make PSE a legend drug and impact on their
practice and patients.
This research has been approved by the University of Kentucky Institutional Review
Board and utilizes survey methodology to obtain opinions of Kentucky pharmacists regarding the
recent proposed legislation to make PSE a legend drug. Survey questions included perceived
efficacy of current precursor controls, anticipated impact on individual pharmacy practice and
patients and current opinion in regards to the proposed legislation. For this project, all surveys
were conducted anonymously with no identifying information collected. A simple random
sample of pharmacists (n=2000) was drawn from a list of all licensed pharmacists in the
Commonwealth of Kentucky, excluding pharmacists with an out-of-state practice address. The
survey response rate was 30.6%. Pharmacists practicing in a hospital or “other” setting were
excluded from the analysis, as their practice sites are not directly impacted by PSE sales. The
final group for analysis included 431 pharmacists practicing in a chain or independent
community pharmacy setting.
Descriptive statistics were generated, including frequencies and proportions. Bivariate
analyses were conducted using the Chi-squared test and t-test. Multivariate logistic regression
was performed to investigate the impact of independent variables on pharmacists’ support of or
opposition to the legislation to make PSE available by prescription-only. Independent variables
utilized in the regression model include: chain versus independent pharmacist status, anticipated
impact of making PSE prescription-only on time spent on PSE-related activities and pharmacy
profits, Kentucky region of pharmacy practice, anticipated impact of making PSE prescriptiononly on methamphetamine abuse and laboratory incidents, confidence in identifying patients
utilizing PSE for a legitimate medical purpose and grams of PSE sold per county resident.
The 2012 Pseudoephedrine Survey for Pharmacists showed that 56.2% of Kentucky
pharmacists practicing in a community pharmacy support the proposed legislation to make PSE
available by prescription-only, 30.7% oppose the legislation and 13.1% are unsure. Furthermore,
independent and chain pharmacists significantly differ in the average number of prescriptions
filled per day, number of PSE purchases per day and the number of years in practice. Practice
site significantly impacts support for the proposed legislation with chain pharmacists being 2.90
times more likely to support the legislation to make PSE prescription-only. One possible
explanation for this difference is that independent pharmacists may exhibit more autonomy in the
decision making process to sell or not sell PSE to potential customers. Additional factors that
influence pharmacist support of the legislation include: anticipated impact of making PSE
prescription-only on time spent on PSE-related activities and pharmacy profits, Kentucky region
of pharmacy practice, and anticipated impact of making PSE prescription-only on
methamphetamine abuse and laboratory incidents. Kentucky region of pharmacy practice
appears to have a large impact on pharmacist support of the legislation. Regions, such as
3

western, eastern, and southern Kentucky, associated more strongly with methamphetamine
appear to more strongly support the proposed legislation.
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Background
Methamphetamine Overview
Description of Methamphetamine and History
Methamphetamine is a synthetically produced stimulant medication belonging to the
amphetamine group, which results in activation of the brain. Amphetamines, including
methamphetamine, were widely available in the United States without a prescription until 1951.
During the 1960s, methamphetamine became widely abused and diverted following use as
treatment for heroin addiction. 1 Drug users began injecting methamphetamine intravenously and
obtaining the drug through black markets. In 1971, methamphetamine was rescheduled as a
Schedule II controlled substance by the Drug Enforcement Administration (DEA), which
resulted in an immediate reduction in abuse and diversion.1
In the 1980s, ephedrine and pseudoephedrine (PSE) were approved by the Food and Drug
Administration (FDA) as nasal decongestants for over-the-counter (OTC) use, and shortly after
the approval, resurgence in methamphetamine abuse was observed. Ephedrine and PSE are two
precursor ingredients used in illicit methamphetamine production in clandestine laboratories.2
Today methamphetamine is recognized as medical treatment, available by prescription, for
narcolepsy, attention deficit disorder, attention deficit hyperactivity disorder, depression and
obesity.1 However, given the significant associated risks and adverse effects of
methamphetamine, alternative therapies are generally preferred and medical use of
methamphetamine remains extremely limited.
Methamphetamine Abuse
According to the United Nations Office on Drugs and Crime (UNODC) World Drug
Report 2012, Methamphetamine abuse affected between 14 and 53 million people or 0.3-1.2% of
5

the worldwide population in 2010.3 Methamphetamine can be taken through a variety of routes
including swallowing orally, smoking, snorting or injecting intravenously. The most common
means of illicit methamphetamine use in the United States is through snorting or intravenous
injection.1
Methamphetamine produces an initial euphoric ‘rush’, which often prompts the user to
continue using methamphetamine. After continued use of methamphetamine, anorexia, weight
loss, insomnia, aggression, hallucinations, paranoia, convulsions, stroke, cardiac arrhythmia, and
hyperthermia may occur.2 As chronic abuse occurs, irreversible brain and heart damage, memory
loss, psychotic behavior, rages, violence and ultimately the inability to care for oneself and one’s
children is often observed.2 In addition to the known physical and emotional harms associated
with methamphetamine abuse, methamphetamine production is associated with significant
harms.
Methamphetamine Production and Description of Pseudoephedrine
Prior to the 1971 rescheduling as a Schedule II controlled substance, methamphetamine
was primarily obtained through the black market, which consisted of diverted supplies from
pharmaceutical companies, distributors and physicians. 1 Upon the rescheduling, illicit
methamphetamine laboratories began emerging. Initially, methamphetamine was produced using
two organic compounds, phenyl-2-propanone (“P2P”) and methylamine, as precursor chemicals.4
Motorcycle gangs manufactured and distributed methamphetamine beginning in San Francisco
and spreading along the Pacific Coast and then moving westward. 4
In 1980, phenyl-2-propanone became a Schedule II controlled substance, and
manufacture shifted towards using OTC ephedrine and PSE as chemical precursors to produce
methamphetamine through a reduction method.4 The reduction method proved to be simpler and
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led to a more potent form of methamphetamine. Today, the DEA estimates that more than 80%
of methamphetamine in the United States comes from clandestine “super” labs in Mexico and
California, which are operated by Mexican drug trafficking organizations.1 The remaining 20%
of methamphetamine in the United States is reported to come from small, amateur, clandestine
laboratories.1 Small quantities of methamphetamine are relatively easy and cheap to manufacture
and little knowledge, skill or equipment is necessary. However, small-scale, clandestine
laboratories are extremely dangerous due to the nature of the volatile chemicals used in the
manufacturing process.1 Fires, explosions and environmental contamination are common. 1
Laboratory seizures have been reported in a wide range of locations, including “sleeping areas,
kitchens and eating areas where food is prepared and stored, garages, vehicles, hotel and motel
rooms, storage lockers, mobile homes, apartments, ranches, campgrounds, rural and urban
dwellings, abandoned dumps, restrooms, houseboats, and other locations” which represents a
large public safety concern.1 According to the DEA National Seizure System, a record number of
methamphetamine laboratory seizures was reported in 2010 and the number of seizures has
increased steadily since 2005, as shown in Figure A.5
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Figure A. Reported Methamphetamine Laboratory Seizures in the United States, by Capacity,
2005-2010

Source: U.S. Department of Justice National Drug Intelligence Center, National Drug Threat
Assessment 20115
Today, amateur, clandestine laboratories obtain PSE largely through a process called
“smurfing”. Federal legislation restricts the amount of PSE that may be purchased OTC by an
individual (see Methamphetamine Precursor Control Legislation below). In order to circumvent
the quantity limitation of PSE, a group of individuals is paid “to go from store to store making
purchases of products containing pseudoephedrine or ephedrine under the threshold
requirements…this process was and is repeated day after day in store after store”.6 Furthermore,
the individuals evade any logbook or electronic system by using various forms of identification.
Methamphetamine Precursor Control Legislation
Federal Laws
A series of federal laws have been enacted in order to control access to methamphetamine
precursor chemicals. Federal methamphetamine precursor laws have been aimed at increasing
reporting and record keeping requirements, requiring registration with the DEA, implementing
packaging requirements, quantity limits, and placement behind the pharmacy counter. Federal
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laws have targeted bulk precursor chemicals, OTC products containing PSE and combination
products containing PSE. Table 1 summarizes the major federal laws implemented to control
methamphetamine precursor chemicals.2
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Table 1. Summary of Federal Efforts to Limit Access to Methamphetamine Precursors
Act
Primary Implications
Year
Chemical Diversion and
Regulated bulk ephedrine and PSE by requiring
1988
Trafficking Act (CDTA)
record keeping, reporting requirements, and
import/export notifications. Did not include OTC
tablets, capsules and other products containing
ephedrine or PSE.
Domestic Chemical
Diversion Control Act
(DCDCA)

Required distributors, importers and exporters to
register with the DEA and gave the DEA power to
revoke registration. Additionally, removed the
record-keeping and reporting exemption for single
entity ephedrine products.

1993

Comprehensive
Methamphetamine Control
Act (MCA)

Broadened federal regulation of chemicals to
include combination OTC medicines containing
precursor ingredients and increased penalties for
methamphetamine and methamphetamine precursor
trafficking and production.

1996

Methamphetamine AntiProliferation Act (MAPA)

Established quantity restrictions for a single
purchase of OTC medications containing ephedrine,
PSE and phenylpropanolamine. Additionally, new
packaging precursor quantity limitations were
included in MAPA.

2000

Combat Methamphetamine
Epidemic Act (CMEA)

Included the following key requirements:
 Quantity limit of 3.6 grams of precursor base
(PSE) per customer per day and 9 grams per
customer per month;
 Store all methamphetamine precursor containing
products behind the counter;
 Maintain a logbook for two years containing the
time and date of sale, name and quantity of
product sold and name and address of each
purchaser;
 Require purchasers to present identification and
sign the logbook.

2005

Combat Methamphetamine
Enhancement Act

Placed restriction on distributors and retailers who
sell products used in illicit methamphetamine
manufacture.

2010
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Multiple studies have examined the impact of early federal methamphetamine precursor
regulations on a variety of indicators of methamphetamine use and production. A 2003 study by
James Cunningham and Lon-Mu Liu examined the impact of four federal ephedrine and PSE
regulations that were implemented between 1989 and 1997on methamphetamine-related hospital
admissions in California. Three regulations focused on large-scale laboratories, while one
regulation targeted small-scale clandestine laboratories by regulating combination ephedrine
products. The study showed a 35-71% drop in methamphetamine-related hospital admissions
following the implementation of each of the regulations targeting large-scale clandestine
laboratories.7 However, the reduction in admissions resurged beginning 6-24 months after each
regulation was implemented. No effect was seen following the regulation targeting small-scale
clandestine laboratories. The study noted possible reasons for the resurgence of admissions,
including producers accessing alternative supplies of precursors and importing precursors from
foreign countries.
A 2005 study by Cunningham and Liu investigated the impact of federal precursor
chemical regulations on methamphetamine related arrests in California. The study examined the
impact of the same four federal methamphetamine precursor regulations as the 2003 study. The
study concluded that methamphetamine arrests stopped rising and decreased by 31-45%
following the implementation of each of the three regulations involving large-scale producers.7
However, little or no effect was seen following the implementation of the regulation involving
small-scale producers. Additionally, arrests rebounded fully within two to three years, which is
likely due to the fact that producers were able to circumvent regulations or the increased
regulations pushed users into self-production.
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A 2008 study by Cunningham and Liu examined the impact of methamphetamine federal
precursor chemical regulations on the demand for drug treatment. The study showed a decline in
voluntary methamphetamine treatment admissions following the precursor regulations of 1995
and 1997 by 39% and 31%, respectively.7 However, the first decline rebounded within two years
and the second rebounded within four years.
The 2011 study conducted by Nonnemaker, Engelen and Shive examined the impact of
retail-level methamphetamine precursor laws in reducing indicators of domestic production,
methamphetamine availability, and consequences of methamphetamine use. The implementation
of MAPA and a state level restriction, the California Uniform Controlled Substances Act
(UCSA), enacted in 2000 was studied. The California UCSA further restricted precursor access
by including all ephedrine and PSE products, regardless of packaging. The study found no
evidence of a decrease in methamphetamine indicators following implementation of the federal
MAPA and some evidence for the effect of the California UCSA. 8 Overall, rises in
methamphetamine purity and lower prices have called into question the net benefit of domestic
precursor controls. The authors suggest that the strict domestic control of methamphetamine
precursors may be causing unintended consequences as seen by increased supply from
international trafficking.
State Laws
In addition to the federal legislation regarding methamphetamine precursor control, many
states have enacted additional laws to further control the sale of PSE and ephedrine. A variety of
additional methamphetamine precursor control laws have been enacted across the United States.
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Electronic Tracking and Block of Sales
Following the passage of CMEA, pharmacies and retail outlets were required to maintain
a logbook of individual PSE sales. While the logbook requirement can be effective at preventing
excessive PSE purchasing within a single store, the legislation did not actively prevent
purchasing PSE from multiple stores, as seen in the practice of smurfing. Multiple states have
implemented regulations which require the electronic tracking of PSE purchases. Electronic
tracking utilizes the purchaser’s driver’s license or alternate identification and records the date
and amount of PSE sold. The data is stored centrally and can be shared among all stores within
the network to prevent the purchase of PSE that would exceed the legal limit. As of July 2011,
twenty states have passed electronic tracking laws. 2 The most common electronic tracking
system utilized by states is National Precursor Log Exchange (NPLEx). 2 NPLEx is provided by
the National Association of Drug Diversion Investigators (NADDI) free of charge, and the
program is sponsored by manufactures of OTC PSE products.
Purchase Quantity Restrictions
The 2005 CMEA restricted retail purchases of PSE to 9 grams per 30 days. 2 However,
five states, as of December 2011, have implemented more stringent laws restricting PSE
purchase to between 6 and 7.5 grams per 30 days.2 The maximum daily dose of PSE is 240mg
per day, which corresponds to a thirty day maximum dose of 7.2 grams. Thus, a quantity
restriction of 7.2 grams per 30 days should not impact individuals purchasing PSE for legitimate
uses.
Schedule V Controlled Substance
As of December 2011, eleven states have reclassified PSE as a Schedule V controlled
substance.2 Schedule V products are available OTC. However, additional requirements exist
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including maintaining a log of all transactions, requirement for proof of age (18 years or older)
and restriction to purchase in a pharmacy. Furthermore, states with prescription monitoring
programs (PMPs) that include Schedule V controlled substances may require transmission of
data to the PMP.
Methamphetamine Registry/Block of Sales to those with Previous Methamphetamine-related
Convictions
Oklahoma passed legislation in 2010 which requires all individuals convicted of
possession, manufacture, distribution or trafficking of methamphetamine to register with the
state.2 Additionally, the registered individuals are prohibited from purchasing and possessing
PSE. The convicted methamphetamine registry is linked with the electronic PSE tracking system
and blocks sales to individuals with methamphetamine-related convictions, regardless of quantity
limitations.2
Prescription-only Status/ Schedule III Controlled Substance
Two states, Oregon and Mississippi, have made PSE a Schedule III controlled substance
available by prescription-only.2 Medications which require a prescription to dispense are often
referred to as legend drugs. Arkansas passed legislation in 2011, which requires a prescription
for PSE unless the purchaser can provide an Arkansas Driver’s License or ID card.2
Additionally, the pharmacist must confirm medical need for individuals purchasing products
containing PSE in Arkansas.
The most recent 2012 study by Cunningham, et al., examined the impact of prescriptiononly status of methamphetamine precursor products on clandestine laboratory seizure, an
indicator of laboratory prevalence. Two states, Oregon (7/2006) and Mississippi (7/2010), have
implemented regulations to classify ephedrine and PSE as Schedule III controlled substances
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available by prescription-only.9 The results of the study showed that Oregon’s laboratory
seizures were not significantly affected by the prescription regulation. However, the number of
seizures began declining months before implementation of the regulation and remained low for
more than five years following the prescription precursor regulation. Additionally, the same
trends were seen in Oregon’s border states. On-the-other-hand, laboratory seizures in Mississippi
dropped approximately 50% following prescription regulation of methamphetamine precursors,
while nearby non-border states exhibited increases in laboratory seizures. 9 The study suggested
that states with more laboratory seizures, such as Mississippi, would likely benefit from
prescription precursor regulation, while states with less laboratory seizures and more
methamphetamine trafficking from Mexico, such as Oregon, would experience less benefit from
prescription precursor regulation.
A 2010 study by Hendrickson, Cloutier and Fu examined the impact of the 2006
prescription methamphetamine precursor requirement in Oregon on methamphetamine-related
Emergency Department (ED) visits. The results showed a 35% decrease in the number of
methamphetamine-related ED visits from the pre-legislation period to the post-legislation
implementation period.10
In conclusion, a number of federal laws have been enacted to control access to
methamphetamine precursors. Furthermore, many states have implemented additional legislation
to more strictly control access to methamphetamine precursors. Multiple studies have evaluated
the impact of federal legislation on indicators of methamphetamine abuse. Overall, the studies
have shown an initial impact following implementation of legislation targeting large-scale
methamphetamine production.7,8,11,12 However, the initial decline in methamphetamine indicators
was followed by a rebound. Federal legislation aimed at small-scale methamphetamine
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production has not been shown to have a significant impact on methamphetamine indicators. The
studies evaluating the impact of state legislation on methamphetamine indicators have evaluated
the prescription-only requirements in Oregon and Mississippi. One study showed no change in
Oregon’s laboratory seizures while a second study showed a drop in methamphetamine-related
ED visits in Oregon following the implementation of the prescription-only PSE requirement.9,10
Additionally, the first study showed a 50% drop in laboratory seizures in Mississippi following
the prescription-only PSE requirement and attributed the difference between Oregon and
Mississippi to the greater number of clandestine laboratories in Mississippi and more
methamphetamine importation from Mexico in Oregon. 9
Overview of the Methamphetamine Problem in Kentucky
According to the Report on Methamphetamine and Other Drug Use in Kentucky prepared
by The University of Kentucky Special Commission on the Study of Methamphetamine and
Other Emerging Drugs in Kentucky, lifetime methamphetamine use in Kentucky is estimated to
be 2.6% of the population.13 The report suggests a slight national decline in methamphetamine
use yet a rising methamphetamine problem in Kentucky. The number of laboratory seizures in
Kentucky has risen from 428 in 2008 to 741 in 2009 and 1078 in 2010, as shown in Figure B.14
Despite federal and state legislation aimed at controlling access to methamphetamine precursors,
Kentucky manufactures have been able to find alternate methods for methamphetamine
production and means of circumventing laws and tracking systems. Smurfing is thought to be a
principle method for circumventing PSE quantity restrictions. Furthermore, new production
methods, such as the “one-pot cook” method, which is also called “shake and bake”, have led to
increased production of methamphetamine via less complicated processes. The most common
production method in Kentucky is the “one-pot cook” method.14 In the “one-pot cook” method,

16

all ingredients are combined at the same time in one bottle. The “one-pot cook” method is
particularly dangerous due to the unstable nature of the chemical reactions.14
Figure B. Number of Laboratory Seizures in Kentucky 2001 to 2010

Source: Kentucky State Police Report 14
Methamphetamine as a percentage of total drug cases in Kentucky has been increasing
from 6% of total drug cases in 2007 and 2008 to 9% in 2009 and 11% in 2010. 14 According to
both the Report on Methamphetamine and Other Drug Use in Kentucky and the
Methamphetamine Manufacturing in Kentucky 2010 report, methamphetamine has traditionally
been associated with western and central Kentucky, as shown in Figure C. However, current
trends indicate rising methamphetamine indicators in eastern Kentucky.14
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Figure C. Methamphetamine Laboratory Seizures in Kentucky, 2009

Source: Kentucky State Police Report 14
A recent research letter described the correlation between PSE sales and the number of
clandestine laboratories per county in Kentucky in 2010. 15 The results showed Kentuckians
purchased a mean of 24,664 grams of PSE per county and 1072 laboratories were reported in
Kentucky in 2010.15 A great deal of variability existed in both the amount of PSE sold and
laboratories reported among counties. Counties with a larger number of PSE sales were
associated with a significantly greater number of reported laboratories. The research letter
reports a 1.7% increase in laboratories for every 1 gram increase in PSE purchased per 100
people.15
Current and Proposed Regulation of Methamphetamine Precursors in Kentucky
In addition to the federal regulations controlling access to methamphetamine precursors,
Kentucky has implemented additional methamphetamine precursor regulations. Kentucky
requires electronic tracking and block of PSE sales exceeding the legal limit. Kentucky was the
first state to implement electronic tracking with NPLEx in 2008. 2 Additionally, Kentucky has
recently passed a stricter PSE quantity limit than the federal limit of 9 grams per month. As of
July 2012, Kentucky law limits PSE monthly sales per individual to 7.2 grams.16 New legislation
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also includes the creation of a methamphetamine registry for those convicted of a
methamphetamine-related crime and blocking sales of PSE to individuals listed in the registry.17
Over the past year, a great deal of attention has been focused on the methamphetamine
problem in Kentucky and new legislation regarding methamphetamine precursors has been
proposed. Much controversy has been generated regarding the proposal to make PSE available
by prescription-only.2 Proponents of requiring a prescription to purchase PSE argue that data
from Oregon and Mississippi indicate efficacy in reducing the number of laboratory incidents
and associated hazards in states with a large number of clandestine laboratories.2 Additional data
show a decrease in methamphetamine-related crime, arrest and admission to substance abuse
treatment facilities following implementation of prescription-only PSE mandates.2 However,
further data are needed to ensure the reduction in methamphetamine indicators is sustained.
Additionally, proponents of a prescription-only mandate argue that a majority of OTC PSE
purchased is used for methamphetamine production.2 Proponents believe OTC PSE creates
hazards for the public and law enforcement, which represents a large cost to society.
Opponents of requiring a prescription to obtain PSE reason that the mandate would place
additional burdens on physicians, pharmacists, insurance companies and consumers. 2 Some
believe consumers will face additional costs and inconveniences for repeat doctor visits to obtain
prescriptions for PSE. The Asthma and Allergy Foundation of America (AAFA), which strongly
opposes making PSE available by prescription-only, conducted an online survey in July 2010 of
more than 2,000 adults suffering from asthma, allergies, cold, cough or flu in the preceding
twelve months. According to the survey, 71% of respondents oppose a law that requires a
prescription to obtain PSE, while 66% support a nationwide e-tracking system.18 Most
respondents reported opposing a law that requires a prescription to obtain PSE due to increased
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costs, inconvenience and the thought that the law would be ineffective in decreasing
methamphetamine abuse and target honest citizens. According to the survey, respondents prefer
e-tracking over a prescription requirement due to efficacy and the limited burden placed on law
abiding citizens.18
An analysis of the prescription-only PSE requirement in Oregon was conducted by the
Cascade Policy Institute and funded by a grant from the Consumer Healthcare Products
Association (CHPA). CHPA is a not-for-profit organization which represents manufactures and
distributors of OTC medications, and supports keeping PSE and associated products available
OTC. Multiple studies have found methamphetamine precursor restrictions to be effective in
reducing methamphetamine indicators, at least in the short-term.9,10 However, the analysis by the
Cascade Policy Institute presents evidence of non-significant changes in methamphetamine lab
incidents, similar decreases in treatment episodes when compared to similar states with no
prescription requirement, and no decrease in methamphetamine-related deaths.19 The analysis
also reports added time and expenses involved with additional doctor visits. Added costs could
include the direct cost of the doctor visit, the increased cost of the drug, travel expenses and costs
from lost time and productivity.19 Additionally, the article states that some patients may opt for
less effective treatment or no treatment, which could result in a lower quality of life.
Importance of Studying Kentucky Pharmacist Opinions of the Potential
Reclassification of Pseudoephedrine as a Legend Drug
Data clearly indicate the notable problem of methamphetamine abuse and production in
Kentucky. Methamphetamine production in clandestine laboratories appears to be increasing in
Kentucky and represents a significant hazard and cost to society as a whole. 13,14 While there
appears to be consensus that something must be done to address the methamphetamine problem,
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various solutions have been proposed with some generating a great deal of controversy; the most
notable being the proposed prescription-only mandate for purchase of PSE. To date, quantitative
and qualitative data are available regarding consumers’ opinions of various methamphetamine
precursor controls.18,19 However, there is very limited understanding of the opinions of
healthcare providers, specifically pharmacists, regarding methamphetamine precursor controls.
A 2009 study interviewed twenty Australian community pharmacists-in-charge regarding
their opinions of developments in the Australian OTC medication market, including PSE sales.20
Project STOP is an electronic PSE tracking system in Australia, which consists of an online
database that checks patient identification and recent OTC PSE purchases to support
pharmacists’ determination of the legitimacy of PSE requests. According to the study, Australian
pharmacists deemed Project STOP to be very useful in preventing misuse and abuse of PSE.20
However, some pharmacists reported concern over robberies due to illicit methamphetamine
manufacturers being unable to obtain PSE through legal means. Other concerns about the
program included challenges in pharmacists’ workloads and strained relationships with patients.
Community/retail pharmacists and staff are often busy entering prescriptions into the
computer system, clarifying prescriptions with physicians, verifying patient allergies, checking
for potential drug interactions, processing insurance claims, calling insurance companies to
resolve issues, ensuring the correct medication, dosage, strength and quantity is dispensed to the
patient, and counseling patients on disease states and medications. The processing of OTC PSE
purchases interrupts the pharmacy workflow and requires a pharmacy staff member to stop his or
her current task, obtain customer identification, start the electronic tracking program, enter
customer identification information and information about the product the customer is wishing to
purchase, submit the information and wait for the tracking system to respond with the
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recommendation to dispense or not dispense the PSE. If numerous PSE purchases are requested
daily, a non-trivial amount of time can be spent dispensing PSE and result in a significant
interruption in the pharmacy workflow. Thus, one might speculate integrating PSE into the usual
prescription workflow by making PSE available by prescription-only might alleviate some of the
burden associated with OTC PSE sales. However, concerns over cost and inconvenience will
likely exist. The small sample size and limited geographical distribution of the study represents a
limitation. Additionally, the study was performed via interview and pharmacist responder bias is
a potential limitation.
Students and faculty at the State University of New York at Albany conducted a survey
of New York pharmacists’ opinions of PSE regulations and presented the results at the 2007
American Pharmacists Association Annual Meeting.21 Drug Topics, a non-peer reviewed trade
journal, described the research in a 2008 article.22 One hundred ninety-three New York State
pharmacists were surveyed regarding views on PSE regulations, which required logging of
consumer information for PSE purchases. According to the article, pharmacists in New York felt
the record-keeping for PSE was unduly burdensome and not reducing illicit methamphetamine
production, despite 67% of pharmacists feeling there had been a dramatic decrease in PSE
purchases.22 Additionally, average time spent logging information for PSE purchases was
reported to be 30-38 minutes per week.22 Other pharmacist concerns over the PSE regulations
included lack of a computerized system that could prevent purchases at multiple pharmacies and
consumers switching to phenylephrine-based products (an alternative OTC nasal decongestant
which is not utilized in illicit methamphetamine production) to avoid the inconvenience of
purchasing PSE behind the pharmacy counter without understanding the difference between the
two products.
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The surveys of Australian and New York pharmacists provided a glimpse of the opinions
of pharmacists regarding OTC PSE regulations requiring logging of PSE purchases. However,
there are no known studies to date that have assessed healthcare providers’, including
pharmacists’, opinions of the prescription-only PSE mandate. It is important to understand
pharmacists’ opinions regarding the proposed prescription-only PSE mandate because
pharmacists are perceived to be significantly impacted by PSE distribution and appear
knowledgeable regarding the burdens surrounding PSE distribution. Pharmacists have firsthand
experience providing PSE to customers with legitimate needs. On-the-other-hand, it is likely that
many pharmacists, unknowingly or with unsubstantiated suspicion, have provided PSE to
customers involved in illicit methamphetamine production. Additionally, pharmacists are
extremely familiar with medication barriers and the impact of disparities on patient care.
Pharmacists and pharmacy staff are required to record PSE purchases, which takes time and
leads to questions from patients. PSE regulations can create a strained relationship between
patients and pharmacists, as patients sometimes view pharmacists as restricting access to PSE.
Furthermore, pharmacists and pharmacy staff are put in the unique position to deny access to
PSE, which can cause an uncomfortable situation. Thus, an understanding of pharmacists’
opinions regarding methamphetamine precursor regulation is necessary to appreciate the current
difficulties and perceived efficacy surrounding methamphetamine precursor control and
implications of proposed legislation to make PSE available by prescription-only. By gaining a
better understanding of the issues surrounding PSE sales, it is hoped that effective legislation
may be enacted to reduce methamphetamine production, laboratory incidents and abuse while
causing the least amount of inconvenience and cost to law abiding citizens.
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Methods
This study uses survey methodology to investigate pharmacists’ opinions on the
effectiveness of current methamphetamine precursor controls, proposed legislation to make PSE
a legend drug and the anticipated impact of making PSE a legend drug on Kentucky pharmacists’
practice and patients. This research has been approved by the University of Kentucky
Institutional Review Board. Survey questions included perceived efficacy of current
methamphetamine precursor controls, anticipated impact of proposed legislation to make PSE
available by prescription-only on individual pharmacy practice and patients, and current opinion
regarding the proposed legislation (see Appendix A for copy of 2012 Pseudoephedrine Survey
for Pharmacists). The majority of the questions were fixed response questions. The survey
utilized various types of response categories, including checklists, Likert-type scales, and
multiple-choice. A few questions were partial open-ended with the option to select other and
provide an alternative written answer. One contingency question that was purely open-ended
asked why respondents were unsure of their support for or opposition to a law requiring a
prescription to purchase PSE. Additionally, the survey asked open-ended questions about the
average number of prescriptions filled per day, average number of PSE purchases per day,
county of practice, description of practice site and year of professional degree.
A list of all licensed pharmacists from the Commonwealth of Kentucky was obtained
from the Kentucky Board of Pharmacy for a nominal fee. Pharmacists with an out-of-state
practice address were removed from the list prior to sampling. A simple random sample of
pharmacists (n=2000) was drawn using Stata v11.0 software23 from the list of all licensed
pharmacists in the Commonwealth of Kentucky. For this project, all surveys were conducted
anonymously with no identifying information collected. A cover letter, survey and paid business

24

reply envelope was mailed to the sample of pharmacists on June 11, 2012. A reminder postcard
was mailed to non-responders on June 27, 2012. Survey collection ended October 5, 2012.
Returned surveys were entered and maintained in a Research Electronic Data Capture (REDCap)
survey instrument hosted by the University of Kentucky.24 A unique identification number was
assigned to each responding pharmacist.
Stata v11.0 statistical software was utilized to analyze the data. Descriptive statistics were
generated, including frequencies and proportions (See Appendix B). Bivariate analyses were
conducted using the Chi-squared test and t-test. Multivariate logistic regression was performed to
investigate the impact of independent variables on pharmacists’ support of the legislation to
make PSE available by prescription-only. Independent variables and related hypotheses are
shown in Table 2.
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Table 2. Independent Variables Utilized in Multivariate Regression and Hypotheses
Independent Variables
Hypotheses
Chain versus independent
Chain pharmacists will be more likely to support the
pharmacist status
legislation
Anticipated impact of legislation on Pharmacists anticipating a decrease in time spent on
time spent on PSE-related activities PSE-related activities will be more likely to support the
legislation
Anticipated impact of legislation on Pharmacists anticipating an increase in profits will be
pharmacy profits
more likely to support the legislation
Kentucky region of pharmacy
practice

Pharmacists practicing in eastern, western and southern
Kentucky will be more likely to support the legislation

Anticipated impact of legislation on Pharmacists anticipating the legislation to be effective in
methamphetamine abuse and
decreasing methamphetamine abuse and laboratory
laboratory incidents
incidents will be more likely to support the legislation
Confidence in identifying patients
utilizing PSE for a legitimate
medical purpose

Pharmacists less confident in identifying patients
utilizing PSE for legitimate medical purposes will be
more likely to support the legislation

Grams of PSE sold per county
resident

Pharmacists practicing in counties with more PSE sold
per county resident will be more likely to support the
legislation

The Kentucky regions were derived from the National Survey on Drug Use and Health
(NSDUH), which is conducted by the Substance Abuse and Mental Health Services
Administration (SAMHSA).25 The regions are depicted in Appendix C. The grams of PSE sold
per county resident was obtained from NPLEX.26 All other independent variables were derived
directly from the survey responses.
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Results
Descriptive Results
The 2012 Pseudoephedrine Survey for Pharmacists was returned by 608 pharmacists and
10 surveys were mailed back with an outdated address, yielding a 30.6% response rate.
Pharmacists reporting their practice site as “Hospital” or “Other”, as well as pharmacists not
designating a practice site, were removed from analysis (n=177) because these pharmacists are
not actively engaged with PSE dispensing. The final sample for analysis included the 431
pharmacists practicing in a community pharmacy, which included independent, chain, and
supermarket/mass retailer pharmacy. Chain and supermarket/mass retailer practice sites were
combined and are hereafter referred to as chain pharmacy for simplicity. Table 3 describes the
characteristics of the responding community pharmacists and reported practice site
characteristics.
Table 3. Characteristics of Responding Pharmacists and Practice Sites

Prescriptions/
Day
PSE
Purchases/Day
Years in
Practice
N
Percentage

Independent
Pharmacists
Std.
Mean
Range
Dev.
70–
277.0 148.5
1000

Chain
Pharmacists
Std.
Mean
Range
Dev.
80–
355.5 173.3
1000

All Community
Pharmacists
Std.
Mean
Range
Dev.
70–
325.5 168.3
1000

P-value*

<0.001

4.2

10.2

0–120

13.8

12.6

0–100

10.1

12.6

0–120

<0.001

23.6

16.1
169
39.2%

1–61

18.3

14.4
262
60.8%

1–58

20.3

15.3
431
100%

1–61

<0.001

* P-values for independent versus chain pharmacists

27

The vast majority, 99.5%, of pharmacists reported being at least somewhat
knowledgeable regarding the use of PSE in the production of methamphetamine in cladestine
laboratories. Additionally, a large majority, 97.5%, of pharmacists reported being at least
somewhat knowledgable regarding the recent proposals to make PSE available by prescriptiononly in the Commonwealth of Kentucky (See Figure D).
Figure D.

Pharmacists' Reported Awareness/ Knowledge
Regarding Aspects of Pseudoephedrine
0.5%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

2.6%

11.9%

No Awareness/
Knowledge

50.0%
Somewhat Aware/
Knowledgeable
87.7%
47.4%

Awareness of Utilization of
PSE in Meth Production

Very Aware/
Knowledgeable

Knowledge of Proposed
Laws to Make PSE
Prescription Only
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Pharmacists were questioned regarding perceived efficacy of current PSE controls,
including the NPLEx electronic tracking system and current quantity limitations, in reducing
methamphetamine abuse and laboratory incidents. As shown in Figure E, very few pharmacists
reported that the current PSE controls were “very effective” in reducing methamphetamine abuse
or laboratory incidents. However, the most frequently selected answer was “somewhat
effective”. PSE controls were perceived to be more effective at reducing methamphetamine
abuse than reducing methamphetamine laboratory incidents.
Figure E.

Pharmacists' Perceived Efficacy of Current
Pseudoephedrine Controls
100%

90%
80%
70%

17.6%

23.3%

27.4%

29.1%

26.7%

27.4%

Not Effective at All

21.7%
23.1%

60%

Somewhat Ineffective

50%
40%
30%

Somewhat Effective
56.9%

50.6%

42.3%

40.8%

20%
10%
0%

Very Effective
3.8%

3.0%

3.5%

2.7%

NPLEx Efficacy NPLEx Efficacy
Quantity
Quantity
at Reducing
at Reducing
Restriction
Restriction
Meth Abuse
Meth Lab
Efficacy at
Efficacy at
Incidents
Reducing Meth Reducing Meth
Abuse
Lab Incidents
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Pharmacists reported a large range in the amount of time required to complete one PSE
purchase using NPLEx, as shown in Figure F. Answers were distributed among < 1 minute, 1 – 2
minutes, 2 – 3 minutes, 3 – 4 minutes and > 4 minutes.
Figure F.

Time to Complete One Pseudoephedrine
Purchase using NPLEx

> 4 minutes
12.2%
3 – 4 minutes
16.5%

2 – 3minutes
23.4%

< 1 minute
21.2%

1 – 2 minutes
26.7%

(n = 401)
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When questioned about the anticipated efficacy of making PSE a legend drug (i.e.
requiring a prescription for purchase), approximately 77% of pharmacists reported that the
legislation would be at least somewhat effective at reducing methamphetamine abuse and
laboratory incidents, as shown in Figure G.
Figure G.

Pharmacists' Anticipated Efficacy of a
Prescription Only Pseudoephedrine Mandate
100%

12.9%

12.4%

90%

10.0%

9.8%

Not Effective at All

80%
70%
60%

39.0%

41.4%

50%

Somewhat
Ineffective
Somewhat Effective

40%
30%
20%

38.1%

36.4%

Very Effective

10%
0%
Rx-Only Efficacy at Reducing
Meth Abuse

Rx-Only Efficacy at Reducing
Meth Lab Incidents

Note: “Rx-Only” refers to the proposed prescription only mandate
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Pharmacists were questioned regarding the anticipated impact of making PSE available
by prescription-only on their own pharmacy practice and patients. Nearly half, 48.8%, of
pharmacists reported an anticipated decrease in time spent on PSE-related activities if PSE were
to be made available by prescription-only, while 31.7% of pharmacists reported an anticipated
increase in time spent on PSE-related activities, as shown in Figure H.
Figure H.

Anticipated Time Impact of Making
Pseudoephedrine Available by Prescription Only

Decrease in Time
48.8%

Increase in Time
31.7%

No Change
19.5%

(n = 416)
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Most pharmacists, 47.9%, reported an anticipated neutral financial impact if PSE were to
be made available by prescription-only. However, a large percentage, 23.8%, reported being
uncertain of the financial impact on their pharmacy if a prescription were required to obtain PSE
(see Figure I).
Figure I.

Anticipated Financial Impact of Making
Pseudoephedrine Available by Prescription Only

Uncertain
23.8%

Reduced profits
19.5%

Increased profits
8.8%
Neutral financial
impact
47.9%

(n = 420)
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Pharmacists reported that patients would be impacted in a variety of ways if PSE were to
be made available by prescription-only. A majority, 72.2%, of pharmacists reported patients
would experience increased time at physicians’ offices obtaining a prescription for PSE.
Additionally, 69.4% and 67.3% of pharmacists reported limited access to PSE for illicit and
legitimate users, respectively. Over half of pharmacists reported an anticipated increase in patient
time spent at the pharmacy obtaining a prescription for PSE and an increase in patient costs (see
Figure J).
Figure J.

Pecentage of Pharmacists Reporting Impact

Perceived Impact of Pseudoephedrine Prescription
Only Mandate on Patients
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As shown in Figure K, 56.2% of pharmacists support a law to make PSE available by
prescription-only, while 30.7% of pharmacists oppose the law.
Figure K.

Percentage of Phamacists Supporting or
Opposing a Law to Make Pseudoephedrine
Available by Prescription Only
Unsure
13.1%
Oppose
30.7%

Support
56.2%

(n = 427)

Pharmacists reported the primary reason that they support or oppose a law to make PSE
available by prescription-only, as shown in Figures L and M. Additionally, space was provide for
respondents to provide a description of the reason for their stance on the proposed legislation if
they felt their reasoning was not captured by available answers. The vast majority of comments
described why the respondent opposed or was unsure regarding the proposed legislation.
Comments appeared to fall into two major categories. Approximately 35% of the comments
indicated that methamphetamine abusers/manufactures will always find a way around laws and
cited opiates and benzodiazepines as examples of continued abuse and diversion problems
despite a prescription requirement. An additional 35% of the comments reported that the
government would be punishing law-abiding citizens if a prescription-only requirement were to
be implemented. A less common theme was that it is not enough to make PSE prescription-only;
PSE should be made a controlled substance and tracked by the Kentucky All Schedule
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Prescription Electronic Reporting (KASPER) system. Additionally, several comments stated that
pharmacists should use better professional judgment and deny PSE to those who are thought to
be using PSE illicitly. Comments reasoned that pharmacists asking more questions and using
better professional judgment would ultimately result in fewer illicit producers coming to the
pharmacy to purchase PSE. Finally, concern over increased criminal activity (robberies and
threatening behavior towards pharmacy staff) if PSE were made prescription-only was discussed
in several comments.
Figure L.

Primary Reason Pharmacists Support Law
Requiring Prescription for Pseudoepherine
39.0%

40%
35%
30%
25%
20%
15%
10%
5%
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Risk of Meth
Abuse

Decreased Current Laws Restricts
Burden on
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Access to
My
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Pharmacy
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Decreased
Injury Risk
from Meth
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1.70%
Other
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Figure M.

Primary Reason Pharmacists Oppose Law
Requiring Prescription for Pseudoephedrine
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Other

Increased
Burden on My
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Table 4 breaks down pharmacists’ support or opposition of the legislation by region. Regions 1
and 3, which include northern Kentucky, Lexington and Louisville, remain split on the
legislation. However, the remaining regions, which include western, eastern and southern
Kentucky, largely support the legislation. The vast majority, 86.0%, of pharmacists in southern
Kentucky (region 6) support the legislation.
Table 4. Pharmacists Support or Opposition of Legislation Broken Down by Region

Regions
1
Oppose Legislation
Support Legislation
Total
Percentage Pharmacists
Supporting

50
60
110
54.5%

2
13
32
45
71.1%

3
32
35
67
52.2%

4
11
27
38
71.1%

5
12
27
39
71.1%

6
8
49
57
86.0%

Total
126
230
356
64.6%

Bivariate and Multivariate Analyses
An independent group t-test was performed to compare the means of independent versus
chain pharmacist reported PSE sales per day (see Table 4). Chain pharmacists sell significantly
more PSE per day than independent pharmacists (t(406) = -8.0569, p = <0.001). Additionally,
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the t-test was repeated to control for size of the pharmacy by dividing reported PSE sales per day
by the reported number of prescriptions per day times 100% (t(398) = -7.5016, p = <0.001).
Thus, chain pharmacies are selling significantly more PSE than independent pharmacies when
controlling for pharmacy size. Furthermore the independent group t-test was performed to
compare the means of independent versus chain pharmacist reported prescriptions per day
(t(411) = -4.7077, p = <0.001) and to compare the mean number of years in practice (t(423) =
3.5356, p = <0.001).
A 2x2 chi-squared test was performed to compare the anticipated impact on time spent on
PSE-related activities if PSE were available by prescription-only (increase or decrease in time
spent on PSE-related activities, see Figure H) between independent and chain pharmacists. There
was no significant difference between independent and chain pharmacists’ anticipated impact on
time spent on PSE-related activities if PSE were available by prescription-only, p = 0.336. A 2x2
chi-squared test was also performed to compare the anticipated impact on profits if PSE were
available by prescription-only (increase or decrease in profit, see Figure I) between independent
and chain pharmacists. There was no significant difference between independent and chain
pharmacists’ anticipated impact on profit if PSE were available by prescription-only, p = 0.744.
Logistic regression was conducted to determine the impact of selected independent
variables on pharmacists’ support of the proposed legislation to make PSE available by
prescription-only. Regression results are shown in Table 5.
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Table 5. Logistic Regression Model for Pharmacists Supporting the Legislation to Make PSE
Available by Prescription-only
Support Legislation to Make PSE
Odds
Robust Std. 95% Confidence
Available by Prescription-only
Ratio
Error
Interval
2.90*
1.22
1.27 – 6.60
Chain Pharmacists
Anticipated PSE Rx Only Impact on Time
Spent on PSE Activities – Increase in Time
No Change in Time
5.09*
2.75
1.77 – 14.65
Decrease in Time
10.57*
4.71
4.42 – 25.30
Not Applicable
1.02e7*
1.37e7
7.24e5 – 1.43e8
Anticipated PSE Rx Only Impact on
Pharmacy Profits – Reduced Profits
Increased Profits
9.45*
7.98
1.80 – 49.5
Neutral Financial Impact
4.53*
2.34
1.64 – 12.45
Uncertain
3.78*
2.11
1.27 – 11.26
Not Applicable
3.86e-6*
6.02e-6
1.82e-7 – 8.2e-5
Regions – Bluegrass, Comprehend, North
Key
Kentucky River, Mountain, Pathways
4.57*
2.86
1.34 – 15.59
Seven Counties
1.89
1.02
0.66 – 5.44
Communicare and River Valley
8.17*
6.52
1.71 – 39.03
Four Rivers and Pennyroyal
4.04*
2.53
1.19 – 13.79
Adanta, Cumberland River, Lifeskills
7.99*
5.01
2.34 – 27.30
Perceived Efficacy of Making PSE Rx
Only on Reducing Methamphetamine
Abuse – Not Effective
Somewhat ineffective
1.52
1.38
0.26 – 9.02
Somewhat effective
8.22*
6.07
1.94 – 34.93
Very effective
34.05*
30.49
5.89 – 196.97
Perceived Efficacy of Making PSE Rx
Only on Reducing Methamphetamine Lab
Incidents – Not Effective
Somewhat ineffective
2.26
2.07
0.38 – 13.55
Somewhat effective
2.56
1.69
0.70 – 9.32
Very effective
8.47*
6.98
1.68 – 42.60
No opinion
4.92
5.47
0.56 – 43.54
Confidence in Identifying Patients Using
PSE for a Legitimate Purpose – Extremely
Confident
Somewhat confident
0.67
0.28
0.30 – 1.54
Not confident
0.81
0.72
0.14 – 4.58
Not applicable
0.81
1.16
0.05 – 13.54
0.51
0.36
0.13 – 1.99
Grams PSE per County Resident Sold
Note: * P-value <0.05; “Rx-only” refers to the proposed prescription-only mandate
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The logistic regression results showed that chain pharmacists were 2.9 times more likely
to support the legislation to make PSE available by prescription-only versus independent
pharmacists. Pharmacists that anticipated no change in time related to PSE activities or a
decrease in time related to PSE activities if PSE were to be available by prescription-only were
5.09 and 10.57 times more likely to support the legislation, respectively. Anticipated impact on
pharmacy profits was also significantly related to pharmacists’ support of the legislation
requiring a prescription to purchase PSE. Pharmacists reporting an anticipated increase in profits
were 9.45 times more likely to support the legislation and pharmacists reporting a neutral
financial impact were 4.53 times more likely to support the legislation versus pharmacists
reporting an anticipated decrease in profits. The region of pharmacy practice significantly
impacted pharmacists’ support of the legislation. Compared to pharmacists practicing in region
1, which includes northern Kentucky and Lexington (see Appendix C for map), pharmacists
practicing in regions 2, 4, 5, and 6 were 4.57, 8.17, 4.04, 7.99 times more likely to support the
legislation, respectively. Region 3, which includes Louisville, was not significant and reported
results more similar to region 1.
Pharmacists anticipating the legislation to be somewhat effective or very effective at
reducing methamphetamine related abuse were 8.22 and 34.05 times more likely to support the
legislation versus pharmacists reporting that the legislation would not be effective at all. The
results were not significant for anticipated reduction in methamphetamine lab incidents, except
when pharmacists reported the legislation to be very effective in reducing lab incidents.
Pharmacists anticipating the new legislation to be very effective at reducing lab incidents were
8.47 times more likely to support the legislation versus pharmacists anticipating the legislation to
not be effective at all. Interestingly, pharmacists’ reported confidence in identifying patients
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utilizing PSE for a legitimate medical purpose is not significantly related to support of the
legislation. Furthermore, grams of PSE sold per county resident is not significantly related to
support of the legislation.

Discussion
There is currently very little data available about the opinions of healthcare providers,
specifically pharmacists, regarding methamphetamine precursor chemical controls. The only
available studies investigated the opinions of Australian and New York pharmacists regarding
OTC PSE regulations requiring logging of PSE purchases. 20,22 Furthermore, studies funded by
the Asthma and Allergy Foundation of America (AAFA) and the Consumer Health Products
Association (CHPA), which are organizations that largely oppose the proposed prescription-only
PSE legislation, have shown that a majority of consumers oppose legislation requiring a
prescription to purchase PSE and that the legislation would unduly burden law-abiding
citizens.18,19 This study aims to gain a better understanding of Kentucky pharmacists’ opinions of
current precursor controls and proposed legislation to make PSE available by prescription-only.
Hospital and specialty pharmacists were excluded from the analysis in order to focus on
pharmacists practicing in a community pharmacy setting, including independent and chain
pharmacies. Community pharmacists are more visibly impacted by PSE controls. There were
significant differences between independent and chain pharmacists in terms of the reported
number of prescriptions filled per day, number of PSE purchases per day and the number of
years in practice. Significantly more PSE was reported to be sold on a daily basis in chain
pharmacies, 13.8 purchases per day versus 4.2 purchases per day. A potential reasoning could be
the sheer difference in store size and the number of customers entering the pharmacy per day;
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independent pharmacists reported filling an average of 277 prescriptions per day versus 355.5
prescriptions per day in chain pharmacies. On-the-other-hand, several written comments
referenced the push from chain pharmacy management to sell PSE, “Independent pharmacists
are more reserved in selling PSE to patients - chain pharmacists are impacted by store
managers/profit”. It is possible that independent pharmacists feel more empowered to develop
their own store policies in the best interest of patients regarding PSE purchases, while chain
pharmacists are required to follow corporate policies aimed at increasing profits. Additionally,
chain pharmacists were 2.90 times more likely to support the legislation to make PSE available
by prescription-only versus independent pharmacists.
The anticipated efficacy of the proposed legislation to require a prescription in order to
purchase PSE was reported by approximately 77% of pharmacists to be at least somewhat
effective in reducing methamphetamine abuse and laboratory incidents. Despite the large number
of pharmacists reporting at least some anticipated efficacy of the proposed legislation requiring a
prescription to purchase PSE, 56.2% of pharmacists reported supporting a law to make PSE
available by prescription-only and 30.7% of pharmacists reported opposition to the law. The
survey results showed that the majority of pharmacists, approximately 68%, opposing the
proposed legislation reported doing so based on patient specific factors, including increased
patient inconvenience and cost. Only 23.5% of the pharmacists opposing the legislation selected
anticipated inefficacy of the law as the primary reason for opposing the law. On-the-other-hand,
the primary reason pharmacists reported supporting a law requiring a prescription for PSE was
decreased risk of methamphetamine abuse and the second most common reason was the
anticipated decreased burden on the pharmacy. Additionally, the logistic regression model
showed that pharmacists’ anticipated efficacy of making PSE available by prescription-only in
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reducing methamphetamine abuse is significantly related to supporting the legislation.
Pharmacists reporting the legislation to be effective in reducing methamphetamine abuse are
more likely to support the legislation.
An additional interesting result of the survey involves the time requirements for PSE
controls. Pharmacists reported a large range in the time requirements to complete one PSE
purchase using the electronic tracking system, NPLEx. Answers varied from less than one
minute to greater than four minutes to complete one purchase. A potential reason for the wide
variation in reported time to complete one PSE purchase is that pharmacists are not actually
completing PSE purchases and are not fully aware of the time requirement. It is likely that
pharmacy technicians and interns perform the majority of the PSE purchases. An alternative
reason for the wide variation is differing time saving technology among pharmacies. Some
pharmacies are able to simply scan identification cards versus manually entering in patient
information into the NPLEx website. Additionally, pharmacists were asked to report the
anticipated time impact of making PSE available by prescription-only. The majority of
pharmacists, 48.8%, reported an anticipated decrease in time spent on PSE-related activities if
PSE were to be available by prescription-only and 31.7% of pharmacists reported an anticipated
increase in time spent on PSE related activities. However, it has been estimated that the average
prescription takes approximately eight minutes to be filled, yet approximately 88% of pharmacist
reported that one PSE purchase took less than four minutes.27 It appears that a significant portion
of pharmacists either view prescriptions as taking less time to fill than the true time to fill a
prescription or pharmacists perceive PSE purchases to take a more significant amount of time
than reported according to the survey results as shown in figure H. One potential reasoning for
the disconnect is that PSE purchases represent an interruption in the normal workflow of the
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pharmacy, which predominately involves filling prescriptions. None-the-less pharmacists were
more likely to support the legislation if they anticipated a decrease in time spent on PSE-related
activities.
The logistic regression analysis of pharmacists’ support of the legislation to make PSE
available by prescription showed a significant impact of pharmacy practice region on support for
the legislation. Pharmacists practicing in western, eastern and southern Kentucky were
significantly more likely to support the proposed legislation. The odds ratios for these regions
ranged from approximately 4 to 8 when comparing to the northern Kentucky and Lexington
region. Additionally, the descriptive statistics showed that roughly 53% of pharmacists in the
northern Kentucky, Lexington and Louisville regions support the legislation while approximately
71% of pharmacists in eastern and western Kentucky support the legislation. Finally, 86% of
pharmacists in southern Kentucky support the legislation. Traditionally, methamphetamine
production has been associated with western and south central Kentucky, and indicators of
methamphetamine are increasing in eastern Kentucky. 14 The pharmacists practicing in areas most
strongly associated with methamphetamine appear to be more likely to support the legislation to
make PSE available by prescription-only.
Finally, two independent variables were surprisingly not found to have significant impact
on pharmacists’ support of the proposed legislation to make PSE available by prescription-only.
Whether or not a pharmacist is confident in identifying patients utilizing PSE for a legitimate
medical purpose was not found to be significantly related to the support of the legislation. The
hypothesis that pharmacists not confident in identifying patients utilizing PSE for a legitimate
medical purpose would be more likely to support the legislation was not supported by the logistic
regression model. Additionally, pharmacists’ support of the legislation was not found to be
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significantly related to the amount of PSE (grams) sold per county resident. Again, the
hypothesis that pharmacists practicing in counties selling more PSE per county resident would be
more likely to support the legislation was not supported by the logistic regression model. It is
possible that pharmacists are simply not aware of how much PSE is sold per county resident in
comparison to other counties.

Limitations
Several limitations exist in regards to this capstone project. The survey response rate,
while respectable, only represents 30.6% of the total pharmacist sample surveyed. Additionally,
the sample size is relatively small (n=608) and was further reduced to n=431 when hospital
pharmacists and pharmacists practicing in “other” settings were excluded from analysis. The
sample for analysis, while representing strong internal validity, lacks external validity as only
Kentucky pharmacists practicing in a community pharmacy setting were included.
Some of the capstone limitations are simply due to the research survey methodology. The
researcher developed the survey questions and it is possible that important response categories
might have been missing from fixed-choice questions. Additionally, responses are mostly
inflexible and require respondents to select one answer and do not provide much opportunity for
discussion or additional details. Another potential issue with survey methodology is response
bias and self-selection bias. Pharmacists choosing to respond to the survey may be inherently
different from pharmacists not choosing to respond. Unfortunately, given the design of the study,
it is not possible to explore potential differences between responders and non-responders.
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Conclusion and Implications
In conclusion, the results of the 2012 Pseudoephedrine Survey for Pharmacists have shed
some light on the controversial proposed legislation to make PSE available by prescription-only.
Despite current federal legislation and increased Kentucky quantity restrictions and NPLEX
tracking, methamphetamine abuse remains a significant problem in Kentucky. This survey was
conducted in order to gain a better understanding of the issues surrounding the sale of PSE from
the health care provider at the frontline – the pharmacist. By gaining a better understanding of
the issues surrounding the sale of PSE it is hoped that effective, future legislation may be enacted
to reduce methamphetamine production, laboratory incidents and abuse yet result in the least
amount of inconvenience and cost to law abiding citizens.
The survey results showed that 56.2% of Kentucky pharmacists practicing in a
community pharmacy support the proposed legislation to make PSE available by prescriptiononly, 30.7% of pharmacists oppose the legislation and 13.1% of pharmacists are unsure.
Furthermore, independent and chain pharmacists significantly differ in the average number of
prescriptions filled per day, number of PSE purchases per day and the number of years in
practice. Practice site significantly impacts support for the proposed legislation with chain
pharmacists being 2.90 times more likely to support the legislation to make PSE prescriptiononly. One possible explanation for this difference is that independent pharmacists may exhibit
more autonomy in the decision making process to sell or not sell PSE to potential customers.
Additional factors that influence pharmacist support of the legislation include: anticipated impact
of making PSE prescription-only on time spent on PSE-related activities and pharmacy profits,
Kentucky region of pharmacy practice, and anticipated impact of making PSE prescription-only
on methamphetamine abuse and laboratory incidents. Kentucky region of pharmacy practice
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appears to have a large impact on pharmacist support of the legislation. Regions associated more
strongly with methamphetamine such as western, eastern, and southern Kentucky appear to more
strongly support the proposed legislation.
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Appendix B: Descriptive Survey Results
How aware are you regarding the use of PSE in the production of methamphetamine in
clandestine labs?
Frequency
Very aware
Somewhat aware
I am not aware
Total Respondents

Percentage (%)
377
51
2
430

87.7
11.9
0.5

How knowledgeable are you regarding the recent proposals to make PSE a legend
(unscheduled) drug available by prescription-only in the Commonwealth of Kentucky?
Frequency
Very knowledgeable
Somewhat knowledgeable
I have no knowledge
Total Respondents

Percentage (%)
204
215
11
430

47.4
50.0
2.6

To what extent do you believe the current National Precursor Log Exchange (NPLEx), formerly
MethCheck, is effective at reducing methamphetamine-related abuse?
Frequency
Not effective at all
Somewhat ineffective
Somewhat effective
Very effective
I have no opinion
Total Respondents

Percentage (%)
74
91
239
16
10
430

17.2
21.2
55.6
3.7
2.3

To what extent do you believe the current National Precursor Log Exchange (NPLEx), formerly
MethCheck, is effective at reducing methamphetamine-related lab incidents?
Frequency
Not effective at all
Somewhat ineffective
Somewhat effective
Very effective
I have no opinion
Total Respondents

Percentage (%)
94
93
204
12
20
423

22.2
22.0
48.2
2.8
4.7
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On average, how long does it currently take your pharmacy to use NPLEx to complete one PSE
purchase?
Frequency
< 30 seconds
30 seconds – 1 minute
1 – 2 minutes
2 – 3minutes
3 – 4 minutes
> 4 minutes
N/A
Total Respondents

Percentage (%)
26
59
107
94
66
49
26
427

6.1
13.8
25.1
22.0
15.5
11.5
6.1

To what extent do you believe the current retail sales quantity restriction of PSE (9 grams per
month) is effective at reducing methamphetamine-related abuse?
Frequency
Not effective at all
Somewhat ineffective
Somewhat effective
Very effective
I have no opinion
Total Respondents

Percentage (%)
116
113
179
15
7
430

27.0
26.3
41.6
3.5
1.6

To what extent do you believe the current retail sales quantity restriction of PSE (9 grams per
month) is effective at reducing methamphetamine-related lab incidents?
Frequency
Not effective at all
Somewhat ineffective
Somewhat effective
Very effective
I have no opinion
Total Respondents

Percentage (%)
119
112
167
11
15
424

28.1
26.4
39.4
2.6
3.5

To what extent do you believe making PSE a legend drug (unscheduled) available by
prescription-only would be effective at reducing methamphetamine-related abuse?
Frequency
Not effective at all
Somewhat ineffective
Somewhat effective
Very effective
I have no opinion
Total Respondents

Percentage (%)
55
43
167
163
1
429

12.8
10.0
38.9
38.0
0.2
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To what extent do you believe making PSE a legend drug (unscheduled) available by
prescription-only would be effective at reducing methamphetamine-related lab incidents?
Frequency
Not effective at all
Somewhat ineffective
Somewhat effective
Very effective
I have no opinion
Total Respondents

Percentage (%)
52
41
174
153
6
426

12.2
9.6
40.9
35.9
1.4

If PSE were to be available by prescription-only, how significant of an impact on your
pharmacy would you anticipate?
Frequency
Increase in time spent on PSE
related activities
No change in time spent on PSE
related activities
Decrease in time spent on PSE
related activities
Not applicable for my practice
setting
Total Respondents

Percentage (%)
132

30.9

81

19.0

203

47.5

11

2.6

427

If PSE were to be available by prescription-only, what financial impact would you anticipate
to your pharmacy?
Frequency
Reduced profits
Increased profits
Neutral financial impact
Uncertain
Not applicable for my practice
setting
Total Respondents

Percentage (%)
82
37
201
100
10

19.1
8.6
46.7
23.3
2.3

430
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How confident do you feel in your ability to identify your patients who are using PSE for a
legitimate medical purpose?
Frequency
Extremely confident
Somewhat confident
Not confident
Unknown
Not applicable for my practice
setting
Total Respondents

Percentage (%)
132
256
28
4
5

31.1
60.2
6.6
0.9
1.2

425

How would making PSE available by prescription-only impact your patients? Check all that
apply.
Frequency
Increase in patient time spent at
physician’s office obtaining
prescription for PSE
Increase in patient time spent in
the pharmacy getting a
prescription for PSE filled
Increase in financial costs for
patients
Limit access to PSE for those
with legitimate needs
Limit access to PSE for those
attempting to illegally produce
methamphetamine
Reduce risk of
methamphetamine abuse
Reduce risk of injury sustained
from unsafe methamphetamine
clandestine labs
No impact

Percentage (%)
311

72.2

245

56.8

240

55.7

290

67.3

299

69.4

222

51.5

212

49.2

3

0.7

At this time, do you support or oppose a law that would require a prescription in order to
obtain PSE?
Frequency

Support
Oppose
Unsure
Total Respondents

Percentage (%)
240
131
56
427

56.2
30.7
13.1
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Please indicate the primary reason why you support a law that would require a prescription
in order to obtain PSE? Select one.
Frequency
Reduces risk of
methamphetamine abuse
Reduces risk of injury from
clandestine lab
Decreased burden on my
pharmacy dealing with people
trying to purchase PSE behind
the counter
Current laws requiring electronic
tracking of PSE are ineffective
Restricts access to only those
who need the medication
Other
Total Respondents

Percentage (%)
94

39.0

11

4.6

55

22.8

42

17.4

35

14.5

4
241

1.7

Please indicate the primary reason why you would oppose a law that would require a
prescription in order to purchase PSE? Select one.
Frequency
Increased cost to patients
Increased inconvenience to
patients
Law would be ineffective
Increased burden on my
pharmacy to fill additional
prescriptions
Other
Total Respondents

Percentage (%)
43
50

31.6
36.8

32
2

23.5
1.5

9
136

6.6

On average, how many prescriptions does your pharmacy fill each day?
Mean

Std. Dev.
325.5

Median
168.3

300
Total Respondents

Range
70 - 1000
411

On average, how many PSE purchases are made at your pharmacy each day?
Mean

Std. Dev.
10.1

Median
12.6

5
Total Respondents

Range
0 - 120
408
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What best describes your practice site? Select one.
Frequency
Independent Pharmacy
Chain/ Supermarket/ Mass
Retailer Pharmacy
Total Respondents

Percentage (%)
169
262

39.2
60.8

431

Number of Years in Practice. (Derived from “In what year did you receive your professional
degree?”)
Mean

Std. Dev.
20.3

Median
15.3

18
Total Respondents

Range
1 - 61
423
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Appendix C: Kentucky Regions25
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